Exploring DCCR as an Important Therapeutic Option for PWS

Time: 5:20 pm
day: Day Two

Details:

  • Elucidating the mechanism of action for the DCCR development program for PWS
  • Evaluating the dose rationale for future studies
  • Regulatory back and forth for advancing phase 3 program, outcomes and key learnings

Speakers: